Statement Issued to Shareholders on the 26th
"Second Phase 3 Results to Be Analyzed by External CRO"

Kolon TissueGene has issued an official apology regarding the failure of the Phase 3 clinical trial of its cell and gene therapy for osteoarthritis, TG-C, in the United States. On the 26th, CEOs Nomun Jong and Jeon Seungho posted a statement titled "To Our Shareholders" on the company's website, saying, "We deeply apologize for the disappointment and concern caused to our shareholders by the first announcement of the TG-C Phase 3 trial results in the United States," and added, "We are taking these results with the utmost seriousness."


Nomun Jong and Jeon Seungho, CEOs of Kolon TissueGene, are answering questions at a press conference announcing the results of the TG-C Phase 3 clinical trial in the United States, held on the 21st at Kolon One & Only Tower in Gangseo-gu, Seoul. Photo by Yonhap News Agency

Nomun Jong and Jeon Seungho, CEOs of Kolon TissueGene, are answering questions at a press conference announcing the results of the TG-C Phase 3 clinical trial in the United States, held on the 21st at Kolon One & Only Tower in Gangseo-gu, Seoul. Photo by Yonhap News Agency

View original image

The company also announced plans to re-examine the root causes of the failure from the beginning. They explained that Chief Medical Officer (CMO) Andy Wayman is leading a thorough analysis of the lack of statistical significance in this study. They added, "Any additional clinical data obtained in the future will be analyzed without preconceptions and in strict accordance with objective scientific standards," and continued, "Through close consultation with top experts in the field, we will pursue a rational development direction that can be accepted by both shareholders and stakeholders."


For the second Phase 3 clinical trial, which is scheduled for topline results to be released in October, the analysis will be entrusted to an external Contract Research Organization (CRO). This is in response to concerns from shareholders about the company's internal analysis of the first study.


Addressing suspicions of alleged insider trading due to a decline in the stock price prior to the clinical trial results announcement, the company explained that it has strictly prohibited employees from trading company stock. At the same time, the company stated, "We will actively work to resolve these suspicions, including by establishing an independent investigative body."


The two CEOs emphasized, "For nearly 30 years, we have been dedicated solely to the development of TG-C," and added, "We will not rely on excuses or unfounded hope, but will share every step of the process with our shareholders and the market through scientific data and responsible action. The only way to restore lost trust is with clear results." They added, "We are determined to reclaim the honor of 'the world's first cell and gene therapy for osteoarthritis.'"



Previously, on the 20th, Kolon TissueGene announced that in the Phase 3 clinical trial "TG-C 15302" involving 531 patients with knee osteoarthritis, the co-primary endpoints—pain and joint function—failed to demonstrate statistical significance compared to placebo. The company identified a higher than expected placebo response as the cause.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing